翁紹華

SH Ueng 2翁紹華  副研究員
生技與藥物研究所
Email: shueng@nhri.edu.tw

 

EDUCATION

  • Ph.D., Chemistry, National Taiwan University, Taipei, Taiwan
  • B.S., Chemistry, National Taiwan University, Taipei, Taiwan

PROFESSIONAL EXPERIENCES

  • Associate Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health research Institutes, Miaoli, Taiwan (2017- present)
  • Joint Appointment Associate Professor, School of Pharmacy, College of Medicine, National Cheng Kung University (2021-present)
  • Assistant Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health research Institutes, Miaoli, Taiwan (2010- 2017)
  • Joint Appointment Assistant Professor, School of Pharmacy, College of Medicine, National Cheng Kung University
  • Post-doctoral fellow, Department of Chemistry, University of Pittsburgh, Pittsburgh, USA (2009/01- 2009/12)
  • Post-doctoral fellow, Department of Chemistry, University Pierre et Marie Curie-Paris VI, Paris, France (2007/09-2008/09)
  • Post-doctoral fellow, Department of Chemistry, National Taiwan University, Taipei, Taiwan (2005/07-2007/09)
  • Post-doctoral Fellow, Institute of Chemistry and Genomic Research Center, Academia Sinica, Taipei, Taiwan(2004/09-2005/06)
  • Research Assistant, Department of Chemistry, National Taiwan University, Taipei, Taiwan(1997/08-1999/08)

RESEARCH INTERESTS

  1. The discovery of small molecule immunotherapeutic anti-cancer agent.
  2. The central nervous system drug discovery for pain administration.

SELECTED PUBLICATIONS

  1. Lin, S.-Y.;† Tien, Y.-W.;† Ke, Y.-Y.;† Chang, Y.-C.; Chang, H.-F.; Ou, L.-C.; Law, P.-Y.; Xi, J.-H.; Tao, P.-L..; Loh, H. H.; Chao, Y.-S.; Shih, C.; Chen, C.-T.; Yeh, S.-H.;* Ueng, S.-H.* Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone, Bioorg. Chem. 2022, Accepted. (SCI; Category: Chemistry, Organic; Impact factor: 5.307; Ranking: 8/57, 14 %, 2021 JCR) (*co-corresponding author)
  2. Yeh, T.-K.; Song, J.-S.; Chang, P.-W.; Yu, J.-C.; Chang, C.-H.; Liao, F.-Y.; Tien, Y.-W.; Kuppusamy, R.; Li, A.-S.; Chen, C.-H. Chen, C.-W.; Lin, L.-M.; Chang, H.-H.; Huang, C.-H.; Yao, J.-Y.; Wu, M.-H.; Peng, Y.-H.; Hsueh, C.-C.; Hsiao, W.-C.; Chen, P.-H.; Lin, C.-Y.; Hsieh, S.-H.; Shih, C.; Hung, M.-S.* Wu, S.-Y.;* Kuo, C.-C.;* Ueng, S.-H.* Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design, Eur. J. Med. Chem. 2022, 229, 114043. (SCI; Category: Chemistry, Medicinal; Impact factor: 6.514; Ranking: 5/63, 8 %, 2020 JCR) (*co-corresponding author)
  3. Tsou, L. K.; Yeh, S.-H.; Ueng, S.-H.; Chang, C.-P.; Song, J.-S.; Wu, M.-H.; Chang, H.-F.; Chen, S.-R.; Shih, C.; Chen, C.-T.; Ke, Y.-Y.* Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery, Sci. Reports 2020, 10, 16771. (SCI; Category: Multidisciplinary Sciences; Impact factor: 4.380; Ranking: 17/73, 23 %, 2020 JCR) (co-first author)
  4. Peng, Y.-H.; Liao, F.-Y.; Tseng, C.-T.; Kuppusamy, R.; Li, A.-S.; Chen, C.-H.; Fan, Y.-S. Wang, S.-Y. Wu, M.-H.; Hsueh, C.-C.; Chang, J.-Y.; Lee, L.-C.; Shih, C.; Shia, K.-S.; Yeh, T.-K.; Hung, M.-S.; Kuo, C.-C.; Song, J.-S.; Wu, S.-Y.;* Ueng, S.-H.* Unique sulfur-aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-dioxygenase inhibitors, J. Med. Chem. 2020, 63, 1642. (SCI; Category: Chemistry, Medicinal; Impact factor: 7.446; Ranking: 3/63, 5 %, 2020 JCR) (*co-corresponding author)
  5. Chao, P.-K.; Chang, H.-F.; Chang, W.-T.; Yeh, T.-K.; Ou, L.-C.; Chuang, J.-Y.; Hsu, J. T.-A.; Tao, P.-L.; Loh, H. H.; Shih, C.; Ueng, S.-H.; * Yeh, S.-H. * BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine, Neuropharmacology 2020, 166, 107678. (SCI; Category: Pharmacology & Pharmacy; Impact factor: 5.251; Ranking: 54/276, 20 %, 2020 JCR) (*co-corresponding author)
  6. Lin, S.-Y.; Kuo, Y.-H.; Tien, Y.-W.; Ke, Y.-Y.; Chang, W.-T.; Chang, H.-F.; Ou, L.-C.; Law, P.-Y.; Xi, J.-H.; Tao, P.-L.; Loh , H. H.; Chao, Y.-S.; Shih, C.; Chen, C.-T.; Yeh, S.-H.;* Ueng, S.-H.* The in vivo antinociceptive and mu-opioid receptor activating effects of the combination of N-phenyl-2,4-dimethyl-4,5-bi-1,3-thiazol-2-amines and naloxone. Eur. J. Med. Chem. 2019, 167, 312. (SCI; Category: Chemistry, Medicinal; Impact factor: 5.573; Ranking: 5/61, 8 %, 2019 JCR) (*co-corresponding author)
  7. Lin, S.-Y.; Yeh, T.-K.; Song, J.-S.; Hung, M.-S.; Cheng, M.-F.; Liao, F.-Y.; Li, A.-S.; Cheng, S.-Y.; Lin, L.-M.; Chiu, C.-H.; Wu, M.-H.; Lin, Y.-J.; Hsiao, W. Sun, M.; Wang, Y.-H.; Huang, C.-H.; Tang, Y.-C.; Chang, H.-H.; Huang, Z.-T.; Chao, Y.-S.; Shih, C.; Pan, S.-L.; Wu, S.-Y.; Kuo, C.-C.;* Ueng, S.-H.* 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorg. Chem. 2018, 77, 600. (SCI; Category: Chemistry, Organic; Impact factor: 3.926; Ranking: 13/57, 22 %, 2018 JCR) (*co-corresponding author)
  8. Chao, P.-K.; Ueng, S.-H.; Ou, L.-C.; Yeh, T.-K.; Chang, W.-T.; Chang, H.-F.; Chen, S.-C.; Tao, P.-L.; Law, P.-Y.; Loh, H. H.; Cheng, M.-F.; Chen, C.-T.; Shih, C.; Yeh, S.-H.* 1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: a novel opioid receptor agonist with less accompanying gastrointestinal dysfunction than morphine. Anesthesiology 2017, 126, 952. (SCI; Category: Chemistry, Medicinal; Impact factor: 6.523; Ranking: 1/31, 3 %, 2017 JCR) (co-first author)
  9. Chen, S.-R.; Ke, Y.-Y.; Yeh, T.-K.; Lin, S.-Y.; Ou, L.-C.; Chen, S.-C.; Chang, W.-T.; Chang, H.-F.; Wu, Z.-H.; Hsieh, C.-C.; Law, P.-Y.; Loh, H. H.; Shih, C.; Lai, Y.-K.; * Yeh, S.-H.;* Ueng, S.-H.* Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists. Eur. J. Med. Chem. 2017, 126, 202. (SCI; Category: Chemistry, Medicinal; Impact factor: 4.816; Ranking: 4/59, 7 %, 2017 JCR) (*co-corresponding author)
  10. Lin, S.-Y.; Yeh, T.-K.; Kuo, C.-C.; Song, J.-S.; Cheng, M.-F.; Liao, F.-Y.; Chao, M.-W.; Huang, H.-L.; Chen, Y.-L.; Yang, C.-Y.; Wu, M.-H.; Hsieh, C.-L.; Hsiao, W.; Peng, Y.-H.; Wu,J.-S.; Lin, L.-M.; Sun, M.; Chao, Y.-S.; Shih, C.; Wu, S.-Y.; Pan, S.-L.;* Hung, M.-S.;* Ueng, S.-H.* Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy. J. Med. Chem. 2016, 59, 419. (SCI; Category: Chemistry, Medicinal; Impact factor: 6.259; Ranking: 3/60, 5 %, 2016 JCR) (*co-corresponding author)
  11. Wu, J.-S.; Lin, S.-Y.; Liao, F.-Y.; Hsiao, W.-C.; Lee, L.-C.; Peng, Y.-H.; Hsieh, C.-L.; Wu, M.-H.; Song, J.-S.; Yueh, A.; Chen, C.-H.; Yeh, S.-H.; Liu, C.-Y.; Lin, S.-Y.; Yeh, T.-K.; Hsu, J. T.-A.; Shih, C.; Ueng, S.-H.;* Hung, M.-S.;* Wu, S.-Y.* Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening. J. Med. Chem. 2015, 58, 7807. (SCI; Category: Chemistry, Medicinal; Impact factor: 5.589; Ranking: 3/59, 5.1 %, 2015 JCR) (*co-corresponding author)
  12. Cheng, M.-F.; Ou, L.-C.; Chen, S.-C.; Chang, W.-T.; Law, P.-Y.; Loh, H. H.; Chao, Y.-S.; Shih, C.; Yeh, S.-H.;* Ueng, S.-H.* Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists, Bioorg. Med. Chem. 2014, 22, 4694. (SCI; Category: Chemistry, Medicinal; Impact factor: 2.793; Ranking: 24/59, 41 %, 2014 JCR) (*co-corresponding author)
  13. Cheng, M.-F.; Hung, M.-S.; Song, J.-S.; Lin, S.-Y.; Liao, F.-Y.; Wu, M.-H.; Hsiao, W.; Hsieh, C.-L.; Wu, J.-S.; Chao, Y.-S.; Shih, C.; Wu, S.-Y.;* Ueng, S.-H.* Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine-2,3-dioxygenase inhibitors, Bioorg. Med. Chem. Lett. 2014, 24, 3403. (SCI; Category: Chemistry, Medicinal; Impact factor: 2.420; Ranking: 30/59, 51 %, 2014 JCR) (*co-corresponding author)
  14. Chao, P.-K.; Chang, H.-F.; Ou, L.-C.; Chuang, J.-Y.; Lee, P.-T.; Chang, W.-T.; Chen, S.-C.; Ueng, S.-H.; Hsu, J. T.-A.; Tao, P.-L.; Law, P.-Y.; Loh, H. H.; Yeh, S.-H.* Convallatoxin enhance the ligandinduced mu-opioid receptor endocytosis and attenuate morphine antinociceptive tolerance in mice. Sci. Reports 2019, 9:2405. (SCI; Category: Multidisciplinary Sciences; Impact factor: 3.998; Ranking: 17/71, 24 %, 2019 JCR)
  15. Peng, Y.-H.; Ueng, S.-H.; Tseng, C.-T.; Hung, M.-S.; Song, J.-S.; Wu, J.-S.; Liao, F.-Y.; Fan, Y.-S.; Wu, M.-H.; Hsiao, W.-C.; Hsueh, C.-C.; Lin, S.-Y.; Cheng, C.-Y.; Tu, C.-H.; Lee, L.-C.; Cheng, M.-F.; Shia, K.-S.; Shih, C.; Wu, S.-Y. Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1. J. Med. Chem. 2016, 59, 282. (SCI; Category: Chemistry, Medicinal; Impact factor: 6.259; Ranking: 3/60, 5 %, 2016 JCR)
  16. Hung, H.-C.; Liu, C.-L.; Hsu, J. T.-A.; Horng, J.-T.; Fang, M.-Y.; Wu, S.-Y.; Ueng, S.-H.; Wang, M.-Y.; Yaw, C.-W.; Hou, M.-H.* Development of an anti-​influenza drug screening assay targeting nucleoproteins with tryptophan fluorescence quenching, Anal. Chem. 2012, 84, 6391. (SCI; Category: Chemistry, Analytical; Impact factor: 5.695; Ranking: 3/75, 4 %, 2012 JCR)

PATENTS

  1. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Thiazolidinone compounds and use thereof. KR10-2365673, 2022. (Granted)
  2. Ueng, S.-H.; Yeh, S.-H.; Chao, Y.-S.; Loh, H. Opioid receptor modulators and use thereof. CA2,996,281, 2021. (Granted)
  3. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. CN201780015438.9, 2021. (Granted)
  4. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. AU2017229129B2, 2021. (Granted)
  5. Ueng, S.-H.; Yeh, S.-H.; Chao, Y.-S.; Loh, H. Opioid receptor modulators and use thereof. CN201680050364.8, 2020. (Granted)
  6. Ueng, S.-H.; Yeh, S.-H.; Lin, S.-Y.; Shih, C.; Loh, H. Preparation of thiazolidinone compounds and use thereof as opioid receptor modulators. US10,544,113B2, 2020. (Granted)
  7. Ueng, S.-H.; Yeh, S.-H.; Chao, P.-K.; Shih, C. Heterocyclic compounds and use thereof. US15/699,123, 2020. (Granted)
  8. 翁紹華、葉修華、林書玉、石全、羅浩,中華民國專利,噻唑烷酮化合物及其用途。TWI691332B,2020 年。(獲證)
  9. Ueng, S.-H.; Yeh, S.-H.; Chao, Y.-S.; Loh, H. Opioid receptor modulators and use thereof. EP3344997B1, 2020. (Granted)
  10. 翁紹華、葉修華、趙伯寬、石全,中華民國專利,雜環化合物及其用途。TWI650313B,2019 年。(獲證)
  11. 翁紹華、葉修華、趙宇生、羅浩,中華民國專利,鴉片類受體調節劑及其用途。TWI625120B,2018年。(獲證)
  12. Ueng, S.-H.; Yeh, S.-H.; Chao, Y.-S.; Loh, H. Opioid receptor modulators and use thereof. US9,827,228B2, 2017. (Granted)

AWARDS

  1. 2020 年科技部未來科技獎 (雜環化合物及其用途—新穎低副作用鴉片類止痛藥)。
  2. The 13th National Innovation Award, 2016. (A next generation opioid analgesic with novel mode of action and fewer adverse reactions). 2016年第十三屆國家新創獎–學研新創獎 (開發新穎止痛藥-新一代無癮鴉片類止痛劑)。
Share Button

Comments are closed.